3 Things You'll Want to Watch in Valeant Pharmaceuticals' Q2 Results
Good news from Valeant Pharmaceuticals (NYSE: VRX)?
That's what investors got the last time the drugmaker announced its quarterly results. Valeant posted a profit in the first quarter. Its balance sheet was improved. Heck, the company even raised its earnings guidance for the full year.
Valeant provides an update on its second-quarter performance on Aug. 8. Could more good news be on the way? Here are three things you'll want to watch in the company's results.
Source: Fool.com
Bausch Health Companies Inc. Aktie
5,91 €
-1,43 %
Bausch Health Companies Inc. erfreut sich mäßiger Beliebtheit, mit mehr Buy- als Sell-Einschätzungen.
Mit einem Kursziel von 16 € für Bausch Health Companies Inc. zeigt sich ein beachtliches Wachstumspotenzial gegenüber dem aktuellen Kurs von 5.91 €.
